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Purpose of the study
HIV treatment guidelines state that the goal of highly
active antiretroviral therapy (HAART) is to achieve an
undetectable viral load (VL; <50 copies/mL) in HIV-
infected patients. Two new therapies, etravirine (ETR;
TMC125) and raltegravir (RAL), have recently been
approved in the US, both with similar indications for
treatment-experienced HIV-1-infected patients. This anal-
ysis compared the relative cost of reaching this treatment
goal for each therapy.
Methods
The proportion of patients achieving undetectable VL
(<50 copies/mL) was reported in Phase III trials that com-
pared ETR (DUET-1 & 2) or RAL (BENCHMRK 1 & 2) to
placebo, both in the presence of a background regimen
(BR). ETR and RAL have not been compared in head-to-
head trials, so an indirect comparison of efficacy and cost
of treatment at week 24 was made. In both sets of trials,
patients were treatment-experienced, but the composition
of the BR differed. In DUET, all patients received daruna-
vir/ritonavir (DRV/r) as part of their BR, while in the
BENCHMRK trials less than half of the patients received
background DRV/r. Subgroup data from BENCHMRK
provided a 'prior' estimate of the treatment effect modifi-
cation due to DRV/r use. A Bayesian analysis was used,
which adjusted for differences in background DRV/r use
between trials. The current analysis estimated the treat-
ment effect assuming that all patients received back-
ground DRV/r. After adjusting for differences in the trials,
efficacy and US wholesale acquisition drug costs were ana-
lysed.
Summary of results
ETR and RAL demonstrated a similar treatment effect
when adjusting for differences in the BR. Mean odds ratios
(95% confidence interval) vs. placebo were 2.08 (1.64–
2.6) and 1.92 (0.98–3.42) for ETR and RAL, respectively.
Annual drug costs were calculated to be $7,957 for ETR
and $9,855 for RAL.
Conclusion
Both ETR and RAL showed similar efficacy rates in achiev-
ing undetectable VL. As a result, a cost-minimisation
approach can be taken when evaluating the addition of
ETR or RAL to a HAART regimen for treatment-experi-
enced HIV-1-infected patients.
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